![](https://newshub-website-data.s3.ap-southeast-2.amazonaws.com/2023/10/04083442/Ka-Ka-Ting-media-1024x681.jpg)
Researchers at the Centenary Institute have discovered a connection between the health of blood vessels and the development of Alzheimer's disease.
The findings suggest that early interventions aimed at improving blood vessel health offer an avenue for the advancement of new treatments for Alzheimer's.
A progressive brain disorder, Alzheimer's disease causes memory loss, cognitive decline and behavioural changes that can seriously affect a person’s ability to carry out daily activities.
The research study, published in the journal GeroScience, found the presence of senescent blood vessel cells in both Alzheimer's patients and mouse models of Alzheimer's. Senescent cells are aged cells that have lost their ability to divide and function properly.
Dr Ka Ka Ting, the lead author of the study and a researcher in the Centenary Institute's Healthy Ageing Centre said that specific blood vessel cells, called endothelial and perivascular cells, play a crucial role in the forming of the blood-brain barrier, a shield guarding the brain against harmful substances.
“The blood-brain barrier serves as a protective barrier, stopping inflammatory molecules and toxic substances from entering the brain via the bloodstream. Issues can arise if the barrier becomes permeable, ‘leaking’ these toxins into the brain,” said Dr Ting.
Significantly, the researchers found in their study a notable increase in the number of senescent (non-functional) blood vessel cells, in and around the blood-brain barrier and linked with areas of leak during the development of Alzheimer’s in mouse models.
“We believe these non-functioning blood vessel cells weaken the barrier making it more susceptible to inflammatory and toxic substances, potentially exacerbating Alzheimer's symptoms as the disease advances,” said Dr Ting.
Based on their discoveries, the researchers believe that early intervention targeting blood vessel health could hold promise in Alzheimer's treatment. This could involve developing medications that specifically target senescent cells of the blood-brain barrier.
“Our study provides a new perspective on Alzheimer's and the intricate relationship with brain blood vessels, offering a promising new path for therapeutic approaches aimed at treating this disease,” Dr Ting said.
[ENDS]
Publication:
Vascular senescence and leak are features of the early breakdown of the blood-brain barrier in Alzheimer’s disease models. https://link.springer.com/article/10.1007/s11357-023-00927-x
Images:
Dr Ka Ka Ting.
https://drive.google.com/file/d/1BBwPM1IdZ-rPBAkcrYiUEhjACh7Lh7mz/view?usp=sharing
https://drive.google.com/file/d/1B9ezYTFF792UJAL3bZZsZO_zw4QIB029/view?usp=sharing
https://drive.google.com/file/d/1B8S3d84SkOk-6Fatv3J2T4As3GkH9_wD/view?usp=sharing
About us:
About the Centenary Institute
The Centenary Institute is a world-leading independent medical research institute, closely affiliated to the University of Sydney and the Royal Prince Alfred Hospital. Our research focuses on three key areas: cancer, inflammation and cardiovascular disease. Our strength lies in uncovering disease mechanisms and applying this knowledge to improve diagnostics and treatments for patients.
For more information about the Centenary Institute, visit centenary.org.au
Contact details:
For all media and interview enquiries, please contact
Tony Crawshaw, Media and Communications Manager, Centenary Institute on 0402 770 403 or email: t.crawshaw@centenary.org.au